# OnCo record lch-iii (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/lch-iii/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "lch-iii", "NCT00276757" ;
  schema:name "LCH-III"@en ;
  schema:description "The Histiocyte Society's third international trial showed that treating multisystem Langerhans cell histiocytosis for a full year, rather than six months, roughly halves the chance of the disease coming back, while adding methotrexate added nothing but toxicity."@en ;
  schema:url <https://onco.cc/trials/lch-iii/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00276757>, <https://doi.org/10.1182/blood-2012-09-455774>, <https://histiocytesociety.org/LCH-IV> ;
  onco:status "positive" ;
  onco:tag "nci-coverage", "paediatric", "histiocytosis" ;
  onco:phase "3" ;
  schema:startDate "2001-04" ;
  onco:cancers <https://onco.cc/cancers/langerhans-cell-histiocytosis/>, <https://onco.cc/cancers/lch-multisystem/>, <https://onco.cc/cancers/lch-single-system/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/methotrexate/> ;
  onco:institutions <https://onco.cc/institutions/histiocyte-society/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> .